Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer.

Clinical Trials as Topic Cohort Studies Humans Inhibitor of Apoptosis Proteins / administration & dosage Pharmacogenetics Squamous Cell Carcinoma of Head and Neck / drug therapy Tumor Microenvironment / drug effects

Journal

Clinical and translational science
ISSN: 1752-8062
Titre abrégé: Clin Transl Sci
Pays: United States
ID NLM: 101474067

Informations de publication

Date de publication:
01 2022
Historique:
revised: 26 01 2021
received: 05 10 2020
accepted: 28 01 2021
pubmed: 21 3 2021
medline: 4 3 2022
entrez: 20 3 2021
Statut: ppublish

Résumé

Inhibitor of apoptosis proteins (IAPs) regulate apoptosis and modulate NF-κB signaling thereby driving expression of genes involved in immune/inflammatory responses. The orally available IAP antagonist Debio 1143 has potential to enhance tumor response to chemoradiotherapy and/or immunotherapy. Patients with pre-operative squamous cell carcinomas of the head and neck (SCCHN) received: Debio 1143 monotherapy (200 mg/day [D]1-15 +/- 2); Debio 1143 (200 mg/day D1-15 +/- 2) plus cisplatin (40 mg/m

Identifiants

DOI: 10.1111/cts.13002 PMID: 33742767 PMC: PMC8742634
pubmed: 33742767
doi: 10.1111/cts.13002
pmc: PMC8742634
doi:

Substances chimiques

Inhibitor of Apoptosis Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

55-62

Subventions

Organisme : Debiopharm International S.A.

Informations de copyright

© 2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.

Références

Nat Rev Cancer. 2010 Aug;10(8):561-74
pubmed: 20651737
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nat Rev Drug Discov. 2012 Feb 01;11(2):109-24
pubmed: 22293567
Radiother Oncol. 2015 Sep;116(3):495-503
pubmed: 26096848
Curr Opin Oncol. 2004 Jan;16(1):19-24
pubmed: 14685088
Lancet Oncol. 2020 Sep;21(9):1173-1187
pubmed: 32758455
PLoS One. 2012;7(3):e31601
pubmed: 22403616
Sci Rep. 2018 Dec 14;8(1):17862
pubmed: 30552344
Technol Cancer Res Treat. 2004 Feb;3(1):23-32
pubmed: 14750890

Auteurs

Carlos Gomez-Roca (C)

Clinical Research Unit, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.

Caroline Even (C)

Institut Gustave-Roussy, Villejuif, France.

Christophe Le Tourneau (C)

Department of Drug Development and Innovation (D3i), Institut Curie, Paris and Saint-Cloud, France.

Neus Basté (N)

Institut Gustave-Roussy, Villejuif, France.

Jean-Pierre Delord (JP)

Clinical Research Unit, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.

Jerome Sarini (J)

Surgery Department, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.

Sebastien Vergez (S)

Surgery Department, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.

Stephane Temam (S)

Institut Gustave-Roussy, Villejuif, France.

Caroline Hoffmann (C)

Department of Drug Development and Innovation (D3i), Institut Curie, Paris and Saint-Cloud, France.

Philippe Rochaix (P)

Pathology Department, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.

Edith Borcoman (E)

Department of Drug Development and Innovation (D3i), Institut Curie, Paris and Saint-Cloud, France.

Bruno Gavillet (B)

Debiopharm International S.A, Lausanne, Switzerland.

Elisabeth Rouits (E)

Debiopharm International S.A, Lausanne, Switzerland.

Annick Ménétrey (A)

Debiopharm International S.A, Lausanne, Switzerland.

Franck Brichory (F)

Debiopharm International S.A, Lausanne, Switzerland.

Daniela Purcea (D)

Debiopharm International S.A, Lausanne, Switzerland.

Gregoire Vuagniaux (G)

Debiopharm International S.A, Lausanne, Switzerland.

Claudio Zanna (C)

Debiopharm International S.A, Lausanne, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Exploratory window-of-opportunity trial to...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Exploratory window-of-opportunity trial to...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Exploratory window-of-opportunity trial to...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protéines régulatrices de l'apoptose › Protéines IAP › Exploratory window-of-opportunity trial to...
questionsmedicales.fr › Professions de santé › Pharmacologie › Pharmacogénétique › Exploratory window-of-opportunity trial to...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs de la tête et du cou › Carcinome épidermoïde de la tête et du cou › Exploratory window-of-opportunity trial to...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › Exploratory window-of-opportunity trial to...